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Abstract
Peritoneal carcinomatosis is a sign of advanced disease of ovarian cancer. The 
prognosis of ovarian cancer is significantly improved after cytoreductive surgery 
with complete tumor debulking followed by platin based chemotherapy. If cyto-
reductive surgery results in a tumor free situation with remaining tumor less than 
0.25 cm, HIPEC may further improve prognosis. Materials and methods: The 
results of the Krefeld study are presented and the literature is reviewed according 
to overall survival and progression free survival with or without HIPEC. In the 
Krefeld study, patients with ovarian cancer and peritoneal carcinomatosis under-
went cytoreductive surgery. In patients with optimal tumor debulking, HIPEC 
was performed. The peri- and postoperative course was observed. Adverse events 
were recorded after the Clavien-Dindo classification. Results: 43 patients were 
treated with cytoreductive surgery and HIPEC. In all patients an optimal cytore-
ductive situation with remaining tumor less than 0.25 cm was achieved. HIPEC 
was performed with a cisplatin solution (50 mg/m2) at 41°C. The median age of 
the patients was 56 years (range: 32–74 years), the median peritoneal cancer index 
(PCI) was 13 (range: 4–21), the median operation time was 356 minutes (range: 
192–507 minutes). The median time to postoperative systemic treatment with 
chemotherapy was 29 days (range 21–70). There was no postoperative surgically 
associated death. No adverse events were recorded in 16 (37.2%) of 43 patients, no 
grade III or IV adverse events were reported for 33 (76.7%) patients, and no grade 
IV adverse events were reported for 41 (95.3%) patients. Grade III adverse events 
occured in 19 (44.2%) of the 43 patients; a total of 29 grade III adverse events 
were reported in these 19 patients. Grade IV adverse events occured in 3 (7.0%) 
of the 43 patients; a total of 3 grade IV adverse events were reported. Two of them 
resulted in return to the operating room. This was a fistula of the distal small bowel 
caused by drainage and a revision of wound infection. Conclusion: In ovarian 
cancer multiple surgical procedures may be necessary in order to have macroscopi-
cally eradicated tumor tissue. Combined with HIPEC, this seems to have positive 
effects on the survival of patients with peritoneal carcinomatosis. Since we have 
no marked additional adverse events caused by HIPEC in our case series, HIPEC 
seems to be an additional treatment option of peritoneal carcinomatosis in ovarian 
cancer. This statement is strengthened by the literature review in that metaanalysis 
show significant improved OAS and PFS.
Keywords: Hyperthermic intraperitoneal intraoperative chemotherapy, HIPEC, 
ovarian cancer
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1. Introduction
Most patients with advanced ovarian cancer will suffer from recurrence, because 
the five year overall survival for stage FIGO III and IV epithelial ovarian cancer is 
still very low with 20–30%. Thus, gynecologic oncologists are looking for better 
treatment strategies [1].
In most patients with advanced ovarian cancer the spread to the peritoneum 
is the primary site of failure. Thus, it seems reasonable to assess additional local 
treatment strategies apart from maximal tumor debulking. According to prior 
studies the intraperitoneal application of cisplatin is assiciated with a 20-fold higher 
concentration in the intraperitoneal space compared to that measured in plasma 
after intravenous administration. Furthermore it was shown that the combination 
of postoperative intraperitoneal and intravenous (ip/iv) chemotherapy improves 
survival in women with optimally resected stage III ovarian cancer compared with 
iv chemotherapy alone. There are many aspects like treatment-related toxicities, 
adhesion barriers after surgery, dysfunction of implanted i.p. catheters (Tenckhoff 
catheters), the absence of a standard treatment regimen, patients` preference and 
the inconvenience of an inpatientregimen that prevent the integration of ip/Iv 
chemotherapy into clinical routine [2].
2. Review and discussion
HIPEC is usually applied immediately following peritonectomy procedure with 
the aim of directly delivering a heated cytotoxic drug to the peritoneal surface of the 
abdomen. While macroscopic disease is removed by cytoreductive surgery, micro-
scopic disease from the peritoneal surface should be eradicated by HIPEC. There are 
studies showing that hyperthermia enhances penetration of the cytotoxic agent and 
induces tumor cell death by multiple mechanisms including impaired DNA repair, 
inhibition of angiogenesis and induction of apoptosis. The rationale of applicatio of 
HIPEC is that HIPEC eradicates tumors up to a diameter of 2.5 cm. Advantages of 
HIPEC in comparison to postoperative ip chemotherapy are the missing adhesion 
barriers at the time of operation. Furthermore, the effectiveness of intraoperative 
intraperitoneal chemotherapy is increased by the hyperthermic application [3–9].
In our own case series analysis [10] of 43 patients treated with HIPEC (cisplatin 
50 mg/m2 for 60 minutes at 42°C) for advanced or recurrent ovarian cancer there 
was no postoperative death. Adverse events of grade III following the Clavien Dindo 
classification [11] were observed in 44.2% of the patients, which suggests that HIPEC 
with cisplatin 50 mg/m2 after CRS in ovarian cancer is a feasable treatment option. 
Additionally, the time to chemotherapy (TTC) was not markedly prolonged in our 
setting. The main complications are caused by surgery and not by HIPEC procedure. 
The very low rate of insufficiences of anastomoses with only one case of a fistula of 
the small bowel shows the immense importance of the experience of the surgical team.
Yonemura et al. [12] described in their study with CRS and HIPEC for colorectal 
carcinomas one postoperative death caused by pulmonary thromboembolism. 
Grade IV adverse events were observed in 9.9% of cases mainly due to insufficiences 
of anastomosis. Grade III adverse events were reported by Kuijpers et al. [13] in 34% 
of the 960 patients in a simliar trial with a mortality rate of 3%, while Passot et al. 
[14], found an incidence of grade III and IV adverse events in 42% of 216 patients 
(CRS and HIPEC) with peritoneal carcinomatosis (35% ovarian cancer).
Ovarian cancer is a leading cause of cancer related death in women and is often 
only diagnosed at an advanced stage, then with diffuse peritoneal carcinomatosis 
[15–34]. Peritoneal carcinomatosis represents the advanced stage in the evolution of 
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EOC, which has been considered as the main cause of recurrence [23, 35, 36]. Since 
ovarian cancer is mainly confined to the peritoneal cavity, even after recurrence, it is 
an ideal target for locoregional therapy. IP chemotherapy is not a standard treatment 
option because of concerns of excessive toxicity [37–39]. Nevertheless IP chemother-
apy is associated with improved survival of advanced EOC [6–8]. HIPEC and post-
operative IP chemotherapy are differing distinctly from eachother, because HIPEC 
is a single treatment of intraoperative chemotherapy at the time of cytoreductive 
surgery. Some critical aspects of ip chemotherapy may be eliminated by this fact 
[21]. So far, most of the evidence for HIPEC in the treatment of advanced ovarian 
cancer was based on large retrospective series [15–17], a few small non-randomized 
prospective studies [18, 19] and a small randomized trial of low quality in regard to 
study design [20]. These available studies are difficult to interpret and compare due 
to the heterogenicity of the study groups. A clear distinction between primary and 
recurrent disease, extensiveness of peritonectomy surgery, various FIGO stages and 
types of histology is not made, although these aspects in themselves significantly 
influence the outcome. A systemic review of published trials [21] identified 9 com-
parative studies reporting an improvement in survival following CRS and HIPEC 
(+/− CHT) compared with CRS alone (+/− CHT). Morbidity following CRS and 
HIPEC was reported to be between 12% and 33% [21, 22]. The majority of complica-
tions are more likely to be due to the aggressive CRS rather than HIPEC, particularly 
in respect to bowel complications (anastomotic insufficiences, bowel fistula sepsis). 
On the other hand the addition of HIPEC is associated with renal impairment and 
haematological toxicity due to transient bone marrow suppression.
The results of the first RCT for HIPEC for primary ovarian cancer were pub-
lished in 2018 [23]. In this study, hyperthermic intraperitoneal chemotherapy with 
cisplatin 100 mg/m2 was administered at 40°C over 90 min in an open technique. 
Sodium thiosulfate was administered by a six-hour intravenous infusion to prevent 
nephrotoxicity. The hazard ratio (HR) for disease recurrence or death was 0.66 
(95% CI 0.50–0.87, P = 0.003), favouring the HIPEC group. The median PFS was 
14.2 months in the CRS plus HIPEC group versus 10.7 months in the CRS group. 
At 5 years, 50% of the patients in the CRS plus HIPEC group had died versus 62% 
in the CRS group (HR 0.67, 95% CI 0.48–0.94, P = 0.02). The median OS was 
45.7 months versus 33.9 months, showing a 11.8-month survival advantage in the 
CRS plus HIPEC group. There was no significant difference in grade three or four 
adverse events between the two groups (27% vs. 25%, P = 0.76, respectively). There 
was a higher rate of stoma formation in the CRS plus HIPEC group (72% vs. 43%, 
P = 0.04). Despite this, the overall health-related quality of life outcomes did not 
differ between the two groups. To date this is the best evidence that a single admin-
istration of HIPEC given at the time of cytoreductive surgery for ovarian cancer 
may achieve significant benefits in terms of survival without excess morbidity or 
loss of quality of life. However, there has been critique concerning this study, in the 
direction of a possible premature analysis of overall survival, the heterogeneity of 
results between study centres, and the results being applicable to only a small subset 
of patients with ovarian cancer [24]. The HIPEC arm also received an additional, 
high dose of cisplatin compared to the non-HIPEC arm, which in itself might 
explain the improved survival.
This study provided the evidence of survival benefit by HIPEC in patients with 
intervall debulking surgery in advanced EOC. One hast o keep in mind that the 
survival of the group without HIPEC was shorter than that in the Gynecologic 
Oncology Group–172 study perhaps because of the different inclusion criteria 
(intervall debuling surgery versus primary debulking surgery) [40].
In contrast to the results of Van Driehl et al., a smaller Korean RCT on HIPEC 
with 184 women, including only patients with stage 3 and 4 disease, did not 
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demonstrate a significant advantage in terms of five-year survival in the HIPEC arm 
[25]. It is not described in how many patients the remaining tumor mass was less 
than 2.5 mm. In addition, women with extraperitoneal metastatic ovarian cancer 
were also included in the study. However, it is important for HIPEC therapy to have 
minimal residual tumor. Therefore, the Korean study would need to be reevaluated 
from these perspectives to gain valdie insights. For stage IV colorectal carcinoma, 
a recently published phase III RCT HIPEC trial failed to demonstrate a survival 
benefit over systemic chemotherapy after cytoreductive surgery [26].
Which drugs and in what dosage should be used for intraperitoneal chemother-
apy is still unclear. Zivanovic et al. [27] showed in the first prospectively designed 
German HIPEC-ROC-I study of 12 patients with recurrence of ovarian cancer that 
a dose increase from 50 mg/m2 cisplatin to 100 mg/m2 is safe. Although one patient 
in the study experienced renal failure not requiring dialysis, a dose of 100 mg/m2 
cisplatin should be used in future studies. The mean operative time was 463 min-
utes. In all cases, systemic chemotherapy was started within 6 weeks. We used the 
dosage of 50 mg/m2 cisplatin in our study, because at the beginning of the study the 
results of Zivanovic et al. [27] had not been published.
Nevertheless, it is not clear at which point it is appropriate to start postoperative 
systemic chemotherapy (TTC). The most important prognostic factor regarding 
OS is achieving surgical R0 resection. At the same time, Mahner et al. [28] demon-
strated in a systemic review of 3,326 patients from three AGO-OVAR trials [3, 5, 7] 
that delayed initiation of therapy of more than 19 days in R0 resected patients was 
associated with significantly decreased overall survival. In contrast, patients with 
macroscopic residual tumor did not benefit from an earlier start of chemotherapy. 
Hofstetter et al. [29] support these findings. An analysis of the European multicenter 
OVCAD trial in which the median start of chemotherapy was 28 days (range 4 to 
158 days) demonstrated that patients with macroscopic R1 resection had signifi-
cantly worse overall survival, when chemotherapy was started after 28 days or later. 
In contrast, Feng et al. [30] demonstrated in 625 patients with advanced ovarian 
cancer that an interval of up to 6 weeks between cytoreductive surgery and start 
of chemotherapy did not negatively affect overall survival. The median TTC in our 
study was 29 days (range 21–70 days). The late start of therapy with a TTC of 70 days 
was due to a fistula at the ileum that required multiple surgeries.
As already mentioned, surgical R0 resection is the most important prognostic 
factor associated with significantly improved overall survival. When evaluating the 
studies described above, this must be taken into account. In Hofstetter et al. [29], 
63.4% of the patients had R0 resection, whereas in Feng et al. [30], this was 33.4%. 
In our study, R0 resection was achieved in 93% of cases, and only 7% of cases had R1 
resection.
Wu et al. [41] demonstrate in their metaanalysis, that HIPEC can significantly 
improve the OS and PFS of EOC. But so far HIPEC is not accepted as a standard 
treatment in clinical routine [21] because of the heterogeneity of the inclusion 
criteria and the study methods.
Wu et al. [41] demonstrate in their metaanalysis, that HIPEC significantly 
improves the OS and PFS of EOC. But so far HIPEC is not accepted as a standard 
treatment in clinical routine [21] because of the heterogeneity of the inclusion 
criteria and the study methods. Subgroup analysis, which considered study design, 
adjusted for heterogeneity. Nevertheless, there are only two RCTs on HIPEC in 
ovarian cancer. The different lengths of follow-up made it necessary to perform 
further analyses regarding to OS and PFS.
Even in this analysis there is the suggestion that HIPEC could significantly 
improve survival. Consistent with previous studies [23, 42] Wu et al. [41] also 
found that the administration of HIPEC is safe, with limited and less morbidity and 
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mortality compared with no HIPEC group in the majority of included studies. In 
primary EOC patients, Wu et al. demonstrated that HIPEC improved OS, PFS and 
each year survival rate. In addition, these results are consistent with previous meta-
analysis of HIPEC [21] suggesting that the incorporation of HIPEC may result in 
better prognosis of primary EOC [40]. Most previous evidence of a beneficial effect 
from HIPEC in primary EOC has been limited to single-group trials or retrospective 
cohorts [43–48]. Until recently, van Driel et al. [23] reported the first RCT about 
primary EOC and HIPEC with the evidence of HIPEC’s survival benefit in advanced 
EOC after NAC.
Lei et al. [49] perfomed a cohort study from January 2010 to May 2017 at 5 
high-volume institutions in China to compare survival outcomes between PCS 
with HIPEC vs. PCS alone for patients with stage III epithelial ovarian cancer. A 
total of 584 patients with stage III primary epithelial ovarian cancer were treated 
with either PCS alone or PCS with HIPEC. The median follow-up period was 42.2 
(33.3–51.0) months.
In addition, a distinction was made how the resection grade of tumor mass 
affected the 3-year overall survival rate and median survival time. In patients with 
R0 resection with additional HIPEC, median survival was 53.9 months (95% CI, 
46.6–63.7) and 3-year overall survival was 65.9% (95% CI, 60.1%–71.2%). Patients 
with residual tumor who underwent HIPEC therapy had a median survival of 
29.2 months (95% CI, 22.3–45.5) and a 3-year overall survival rate of 44.3% (95% 
CI, 34.6%–53.4%). In patients with complete tumor mass reduction who received 
PCS only, median survival was 42.3 months (95% CI, 31.1–59.3), and 3-year overall 
survival was 55.4% (95% CI, 44.7%–64.8%). Incomplete tumor mass resection 
without HIPEC, exhibits the worst outcome with a median survival of 19.9 months 
(95% CI, 11.6–39.1) and a 3-year overall survival rate of 36.7% (95% CI, 23.4%–
50.1%). This leads to the conclusion that PCS with HIPEC results in significantly 
better overall survival, especially with R0 resection of tumor mass.
In contrast, several studies in the past lead to opposing results. This could be 
due to heterogeneous study designs, different treatment regimens, and different 
inclusion criteria of patients. Mendivil et al. [50] performed a comparative study 
in primary advanced EOC, highlighting survival rates of patients with and without 
HIPEC treatment. Here, a significant PFS advantage was evident in the HIPEC 
group, although overall survival was not prolonged. The reason could be the differ-
ent recruitment period of the cohorts. The control group was recruited much earlier 
(2008–2014) and thus had a longer median follow-up time in contrast to the HIPEC 
group, which was collected in 2012–2015. This could be the reason for the similar 
median OS of both groups. Wu et al. [45] also failed to show a significant PFS 
benefit in their study regarding HIPEC therapy. Interestingly, the rate of complete 
tumor reduction was only 14.58% in the control group and 8.33% in the HIPEC 
group. As shown above, this could have a strong impact on the data analysis.
Additional trials are still needed to determine the optimal time for HIPEC 
administration and whether HIPEC is also effective after primary cytoreductive 
surgery in aprospective randomized trial.
For recurrent ovarian cancer, Wu et al. showed that HIPEC therapy significantly 
increased OS and PFS. These results are in accordance with similar meta-analysis of 
Huo et al. on HIPEC [21]. Cascales-Campos et al. confirmed the results regarding 
significant differences in 2-, 4-, and 5-year PFS with and without HIPEC therapy 
[42]. It is well known that the standard treatment of relapsed EOC is systemic 
chemotherapy. The median OS is less than 30 months [21]. Nevertheless, there is 
evidence that even in relapsed EOS, prognosis can be improved by CRS, provided 
that the tumor can be completely resected [51, 52]. Bristow et al. showed that 
patients who underwent CRS had OS ranging from 41 to 60 months. The PFI was 
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30.3 months [51, 52]. Again, the complete tumor mass reduction was crucial for 
median overall survival (R0 45.2 vs. R1 19.7, HR¼3.71, p < 0.001) [53]. These data 
demonstrates that overall survival in relapsed EOS can be significantly increased by 
CRS. Implementation of CRS in the therapy of relapsed EOC would improve overall 
survival. This may be a reason, which could have led to insignificant difference for 
1- and 2-year PFS for therapy with and without HIPEC. Baiocchi et al. [54] showed 
that overall survival cannot be improved by combining CRS and HIPEC in relapsed 
platinum-sensitive EOC. Further studies are needed for recurrent EOC, especially 
considering tumor resectability.
But this result might be based on a selection bias with regard to the different 
extent of disease or surgery status. It has to be taken under consideration, if the 
result might be based on a selection bias with regard to the different extent of 
disease or surgery status. Spiliotis et al. [20] demonstrated in their randomized trial 
of 120 relapsed EOC patients that the combination of CRS and HIPEC was supe-
rior to CRS only. Surprisingly, overall survival rates were the same in the HIPEC 
cohorts regardless of the presence or absence of platinum resistance. This was not 
the case in the CRS group. The reason for this could be sensitization of tumor cells 
by hyperthermia. It is conceivable that molecular mechanisms, such as heat shock 
proteins or epigenetic changes, could be triggered to sensitize the tumor cells [55, 
56]. Again, complete tumor reduction is shown to prolong median overall survival. 
A limitation could be the randomization process and primary endpoints of the 
study are not clearly defined [23, 57]. In conclusion, further RCS on relapsed EOC 
need to be performed as the study situation is very heterogeneous regarding PFS, 
median follow-up and first-line postoperative treatment [19].
There are some limitations existing in the meta-analysis by Wu et al. First, the 
inclusion criteria and HIPEC drug regimens for EOC are varying with regard to the 
extent of disease status and CRS, to the standardization of IPEC protocols. Second, 
no standard quantitative measurement of the morbidity related to HIPEC was 
established. Third, the potential publication bias of included studies was unavoid-
able due to insufficient RCTs data so far.
It is expected that additional RCS will be performed in the future to elucidate 
the value of HIPEC in primary and recurrent EOC. In previous studies, the common 
thread was the performance of HIPEC following CRS. Platinum and/or paclitaxel 
were usually chosen as therapeutic agents. Only one study evaluated the combina-
tion of cisplatin and doxirubicin.
3. Conclusion
Taken together, Wu et al. support with their meta-analysis that HIPEC therapy 
has a positive impact, both in primary and recurrent EOC on patients’ OS and PFS. 
Nevertheless, no improvement in 1- and 2-year PFS was achieved in recurrent EOC. 
Therefore, especially for relapsed disease, it is essential to design clearly structured 
studies that support the value of HIPEC in the treatment of EOC.
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